Faron Pharmaceuticals Oy reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was EUR 30.94 million compared to EUR 28.73 million a year ago. Basic loss per share from continuing operations was EUR 0.48 compared to EUR 0.52 a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
145 GBX | -3.33% | +13.73% | -52.46% |
Apr. 30 | Faron Pharmaceuticals Ltd. Announces Appointment of Dr. Juho Jalkanen as Director | CI |
Apr. 30 | Faron Pharmaceuticals Oy Announces Chief Executive Officer Changes | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-52.46% | 135M | |
-1.17% | 104B | |
+2.87% | 97.47B | |
+4.05% | 22.25B | |
-14.77% | 21.68B | |
-8.86% | 18.2B | |
-39.98% | 17.02B | |
-13.21% | 16.36B | |
+8.55% | 14.39B | |
+35.75% | 12.37B |
- Stock Market
- Equities
- FARN Stock
- News Faron Pharmaceuticals Oy
- Faron Pharmaceuticals Oy Reports Earnings Results for the Full Year Ended December 31, 2023